Search results
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in...
Morningstar· 3 days ago- At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). PALO ALTO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq ...
BridgeBio data show sustained benefit for achondroplasia drug
BioPharma Dive via Yahoo Finance· 3 days agoLonger follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause...
Texas Supreme Court rejects challenge to state abortion ban's medical exceptions
Fox News via Yahoo News· 6 days agoZurawski said the ruling was "heartbreaking." "I am outraged on behalf of my fellow plaintiffs who...
Texas Supreme Court rejects challenge to abortion ban
KXAN via Yahoo News· 7 days agoThe court held that the medical exceptions in Texas' abortion ban are sufficiently broad, and do not...
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate - BridgeBio Pharma (NASDAQ:BBIO)
Benzinga· 3 days agoTuesday, BridgeBio Pharma Inc BBIO announced sustained results from the PROPEL 2 Phase 2 trial of...
State of Texas: ‘School choice’ plan poised to pass after runoff wins for Abbott-backed candidates
KXAN via Yahoo News· 5 days agoGov. Greg Abbott is declaring victory in his 18-month-long fight for a school choice initiative that...